Skip to main content

Table 6 HOMA-IR segmented subgroup analysis

From: Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study

 

Non-adjusted

Adjust I

Adjust II

P for interaction

HOMA-IR < 3.59

 Age dichotomous

0.4039

  Low

0.73 (0.55, 0.99) 0.0398

0.73 (0.54, 0.98) 0.0339

0.81 (0.59, 1.10) 0.1727

 

  High

0.75 (0.63, 0.89) 0.0012

0.74 (0.62, 0.88) 0.0008

0.94 (0.77, 1.14) 0.5309

 

 Gender

   

0.7908

  Male

0.79 (0.66, 0.93) 0.0055

0.72 (0.61, 0.86) 0.0002

0.88 (0.72, 1.06) 0.1758

 

  Female

0.91 (0.69, 1.19) 0.4804

0.87 (0.66, 1.13) 0.2932

0.92 (0.68, 1.24) 0.5745

 

 Diabetics

   

0.6544

  Yes

0.82 (0.71, 0.95) 0.0089

0.76 (0.65, 0.88) 0.0002

0.88 (0.74, 1.04) 0.1424

 

  No

1.10 (0.46, 2.59) 0.8329

0.95 (0.37, 2.48) 0.9211

1.09 (0.45, 2.65) 0.8545

 

 Cancer

   

0.297

  Yes

0.65 (0.49, 0.86) 0.0027

0.63 (0.47, 0.85) 0.0024

0.77 (0.55, 1.06) 0.1065

 

  No

0.87 (0.73, 1.04) 0.1230

0.81 (0.68, 0.95) 0.0115

0.93 (0.77, 1.12) 0.4529

 

 Hypoglycemic drugs or insulin Users

 

0.8085

  Yes

0.86 (0.73, 1.01) 0.0583

0.73 (0.62, 0.86) 0.0002

0.88 (0.73, 1.05) 0.1642

 

  No

0.73 (0.50, 1.07) 0.1105

0.81 (0.56, 1.18) 0.2788

0.93 (0.63, 1.37) 0.7047

 

 Lipid-lowering drug users

  

0.96

  Yes

0.83 (0.72, 0.97) 0.0162

0.76 (0.66, 0.88) 0.0004

0.89 (0.75, 1.05) 0.1637

 

  No

0.85 (0.41, 1.77) 0.6620

0.77 (0.36, 1.65) 0.5061

0.90 (0.42, 1.95) 0.7988

 

HOMA-IR > 3.59

   

 Age dichotomous

  

0.2771

  Low

1.01 (0.97, 1.05) 0.5769

1.01 (0.98, 1.05) 0.4820

1.00 (0.96, 1.05) 0.8460

 

  High

1.03 (1.00, 1.06) 0.0873

1.04 (1.01, 1.07) 0.0094

1.03 (1.00, 1.07) 0.0657

 

 Gender

   

0.05

  Male

0.99 (0.96, 1.03) 0.7300

1.02 (0.99, 1.06) 0.2589

1.00 (0.97, 1.04) 0.9058

 

  Female

1.05 (1.01, 1.08) 0.0053

1.05 (1.02, 1.09) 0.0038

1.06 (1.02, 1.10) 0.0040

 

 Diabetics

   

0.7656

  Yes

1.02 (0.99, 1.04) 0.1842

1.03 (1.01, 1.06) 0.0053

1.03 (1.00, 1.05) 0.0565

 

  No

0.99 (0.67, 1.44) 0.9381

1.01 (0.67, 1.54) 0.9530

1.10 (0.70, 1.73) 0.6737

 

 Cancer

   

0.0349

  Yes

1.09 (1.04, 1.15) 0.0010

1.12 (1.05, 1.18) 0.0002

1.10 (1.03, 1.17) 0.0043

 

  No

1.01 (0.98, 1.04) 0.5390

1.02 (0.99, 1.05) 0.1266

1.01 (0.98, 1.04) 0.3709

 

 Hypoglycemic drugs or insulin Users

 

0.0716

  Yes

1.01 (0.99, 1.04) 0.2559

1.03 (1.01, 1.06) 0.0109

1.02 (1.00, 1.05) 0.0977

 

  No

1.09 (0.96, 1.24) 0.1717

1.17 (1.03, 1.32) 0.0131

1.17 (1.03, 1.33) 0.0189

 

 Lipid-lowering drug users

  

0.3338

  Yes

1.01 (0.99, 1.04) 0.2313

1.03 (1.01, 1.06) 0.0095

1.02 (1.00, 1.05) 0.0741

 

  No

1.09 (0.96, 1.23) 0.1837

1.11 (0.98, 1.27) 0.1089

1.12 (0.95, 1.32) 0.1699

 
  1. hazard ratio(HR), 95% confidence interval(CI),and P-value. Adjust I: Age, sex, race, diabetes, and cancer. Adjust II: Age, sex, race, diabetes, cancer, and variables obtained by using the two-way effect change method. Variables used as stratification criteria were not adjusted
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840